Exciting results are expected this year, from multiple mid and late stage clinical trials and involving a broad array of adenosine drugs including CD73, CD39 and A2AR!
Join this unmissable 3-day meeting to explore the biology of the receptors and enzymes opening doors to new therapeutic opportunities at the discovery stage, utilize novel technologies and approaches through translation to clinical development to improve patient selection, and discover new ways of finding mono and combo therapy approaches to increase potency and safety.
Top Speakers includes:
- Alex Gaither, Vice president from Exscientia AI – evaluating ways to improve preclinical engineering practices for adenosine mono & combo therapeutics candidates
- Changyun Hu, CSO from Adept Therapeutics – deep diving into preclinical and clinical Adenosine receptor targeting and more
- Joanne Lager, Chief Medical Officer from iTeos Therapeutics – looking beyond T Cell and assessing potential outcomes for the Adenosine field in the event of an approval or major failure
& 15+ more expert speakers!
Download your copy of the newly released agenda to find everything that will help you translate and clinically develop your adenosine therapeutic: https://ter.li/hende5
Interested in speaking? Contact info@hansonwade.com
Interested in sponsoring? Contact sponsor@hansonwade.com